Combination therapy aims to boost blood cells in Hard-to-Treat MDS

NCT ID NCT06020833

Terminated Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether combining roxadustat with retinoic acid can help people with low-risk myelodysplastic syndromes (MDS) whose disease hasn't responded to initial treatment. The goal is to improve blood cell counts and reduce the need for transfusions. Participants will take both drugs orally for 8 weeks, and researchers will measure how many achieve complete or partial remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: roxadustat combined with retinoic acid
What this could lead to: If it works, this combination could offer a new treatment option for people with low-risk MDS who haven't responded to standard therapy, potentially reducing or eliminating the need for blood transfusions.
What could go wrong: This is an early-phase, single-arm trial with no control group, so results are preliminary. The combination may cause side effects or prove no more effective than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

More trials for these conditions

Other studies related to the condition(s) this trial covers.